333 related articles for article (PubMed ID: 16731829)
21. Pioglitazone, a PPAR-gamma ligand, exerts cytostatic/cytotoxic effects against cancer cells, that do not result from inhibition of proteasome.
Mrówka P; Głodkowska E; Młynarczuk-Biały I; Biały L; Kuckelkorn U; Nowis D; Makowski M; Legat M; Gołab J
Acta Biochim Pol; 2008; 55(1):75-84. PubMed ID: 18327303
[TBL] [Abstract][Full Text] [Related]
22. Pioglitazone inhibits the growth of human leukemia cell lines and primary leukemia cells while sparing normal hematopoietic stem cells.
Saiki M; Hatta Y; Yamazaki T; Itoh T; Enomoto Y; Takeuchi J; Sawada U; Aizawa S; Horie T
Int J Oncol; 2006 Aug; 29(2):437-43. PubMed ID: 16820887
[TBL] [Abstract][Full Text] [Related]
23. Rosiglitazone prevents advanced glycation end products-induced renal toxicity likely through suppression of plasminogen activator inhibitor-1.
Yu X; Li C; Li X; Cai L
Toxicol Sci; 2007 Apr; 96(2):346-56. PubMed ID: 17264099
[TBL] [Abstract][Full Text] [Related]
24. Anti-inflammatory effect of antidiabetic thiazolidinediones prevents bone resorption rather than cartilage changes in experimental polyarthritis.
Koufany M; Moulin D; Bianchi A; Muresan M; Sebillaud S; Netter P; Weryha G; Jouzeau JY
Arthritis Res Ther; 2008; 10(1):R6. PubMed ID: 18199331
[TBL] [Abstract][Full Text] [Related]
25. Pioglitazone induces apoptosis in human vascular smooth muscle cells from diabetic patients involving the transforming growth factor-beta/activin receptor-like kinase-4/5/7/Smad2 signaling pathway.
Ruiz E; Redondo S; Gordillo-Moscoso A; Tejerina T
J Pharmacol Exp Ther; 2007 May; 321(2):431-8. PubMed ID: 17267584
[TBL] [Abstract][Full Text] [Related]
26. Pioglitazone reverses down-regulation of cardiac PPARgamma expression in Zucker diabetic fatty rats.
Pelzer T; Jazbutyte V; Arias-Loza PA; Segerer S; Lichtenwald M; Law MP; Schäfers M; Ertl G; Neyses L
Biochem Biophys Res Commun; 2005 Apr; 329(2):726-32. PubMed ID: 15737646
[TBL] [Abstract][Full Text] [Related]
27. Peroxisome proliferator-activated receptor-gamma ligand reduced tumor necrosis factor-alpha-induced interleukin-8 production and growth in endometriotic stromal cells.
Ohama Y; Harada T; Iwabe T; Taniguchi F; Takenaka Y; Terakawa N
Fertil Steril; 2008 Feb; 89(2):311-7. PubMed ID: 17555752
[TBL] [Abstract][Full Text] [Related]
28. SPARC regulates cell cycle progression in mesangial cells via its inhibition of IGF-dependent signaling.
Francki A; Motamed K; McClure TD; Kaya M; Murri C; Blake DJ; Carbon JG; Sage EH
J Cell Biochem; 2003 Mar; 88(4):802-11. PubMed ID: 12577314
[TBL] [Abstract][Full Text] [Related]
29. Glucose-induced reactive oxygen species cause apoptosis of podocytes and podocyte depletion at the onset of diabetic nephropathy.
Susztak K; Raff AC; Schiffer M; Böttinger EP
Diabetes; 2006 Jan; 55(1):225-33. PubMed ID: 16380497
[TBL] [Abstract][Full Text] [Related]
30. The combination of sirolimus and rosiglitazone produces a renoprotective effect on diabetic kidney disease in rats.
Flaquer M; Lloberas N; Franquesa M; Torras J; Vidal A; Rosa JL; Herrero-Fresneda I; Grinyó JM; Cruzado JM
Life Sci; 2010 Jul; 87(5-6):147-53. PubMed ID: 20600147
[TBL] [Abstract][Full Text] [Related]
31. Angiotensin II type 1 receptor expression is increased via 12-lipoxygenase in high glucose-stimulated glomerular cells and type 2 diabetic glomeruli.
Xu ZG; Miao LN; Cui YC; Jia Y; Yuan H; Wu M
Nephrol Dial Transplant; 2009 Jun; 24(6):1744-52. PubMed ID: 19103735
[TBL] [Abstract][Full Text] [Related]
32. Effect of eplerenone, enalapril and their combination treatment on diabetic nephropathy in type II diabetic rats.
Kang YS; Ko GJ; Lee MH; Song HK; Han SY; Han KH; Kim HK; Han JY; Cha DR
Nephrol Dial Transplant; 2009 Jan; 24(1):73-84. PubMed ID: 18682491
[TBL] [Abstract][Full Text] [Related]
33. Modulation of cardiac and aortic peroxisome proliferator-activated receptor-gamma expression by oxidative stress in chronically glucose-fed rats.
El Midaoui A; Wu L; Wang R; de Champlain J
Am J Hypertens; 2006 Apr; 19(4):407-12. PubMed ID: 16580578
[TBL] [Abstract][Full Text] [Related]
34. Pioglitazone attenuates cardiac fibrosis and hypertrophy in a rat model of diabetic nephropathy.
Elrashidy RA; Asker ME; Mohamed HE
J Cardiovasc Pharmacol Ther; 2012 Sep; 17(3):324-33. PubMed ID: 22261714
[TBL] [Abstract][Full Text] [Related]
35. Gene expression regulated by pioglitazone and exenatide in normal and diabetic rat islets exposed to lipotoxicity.
Ghanaat-Pour H; Sjöholm A
Diabetes Metab Res Rev; 2009 Feb; 25(2):163-84. PubMed ID: 19065603
[TBL] [Abstract][Full Text] [Related]
36. Role of peroxisome proliferator-activated receptor-gamma (PPARgamma) during liver regeneration in rats.
Yamamoto Y; Ono T; Dhar DK; Yamanoi A; Tachibana M; Tanaka T; Nagasue N
J Gastroenterol Hepatol; 2008 Jun; 23(6):930-7. PubMed ID: 18565023
[TBL] [Abstract][Full Text] [Related]
37. Pioglitazone inhibits homocysteine-induced migration of vascular smooth muscle cells through a peroxisome proliferator-activated receptor gamma-independent mechanism.
Li L; Gao PJ; Xi R; Wu CF; Zhu DL; Yan J; Lu GP
Clin Exp Pharmacol Physiol; 2008 Dec; 35(12):1471-6. PubMed ID: 18759864
[TBL] [Abstract][Full Text] [Related]
38. Ethyl pyruvate ameliorates albuminuria and glomerular injury in the animal model of diabetic nephropathy.
Ju KD; Shin EK; Cho EJ; Yoon HB; Kim HS; Kim H; Yang J; Hwang YH; Ahn C; Oh KH
Am J Physiol Renal Physiol; 2012 Mar; 302(5):F606-13. PubMed ID: 22129969
[TBL] [Abstract][Full Text] [Related]
39. Delivery of megsin siRNA plasmid reveals therapeutic potential against diabetic nephropathy by down-regulating p27(kip1) level.
Liu M; Zhang Y; Chi Y; Zhai S; Wang B; Shi Y; Li Y
J Nephrol; 2012; 25(3):418-25. PubMed ID: 21928229
[TBL] [Abstract][Full Text] [Related]
40. Insulin resistance accelerates a dietary rat model of nonalcoholic steatohepatitis.
Ota T; Takamura T; Kurita S; Matsuzawa N; Kita Y; Uno M; Akahori H; Misu H; Sakurai M; Zen Y; Nakanuma Y; Kaneko S
Gastroenterology; 2007 Jan; 132(1):282-93. PubMed ID: 17241878
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
